How Government Grants Help Startups Raise Venture Capital

A government grant is one of the strongest signals a startup can send to investors. When a panel of federal experts selects your company from hundreds of applicants and commits taxpayer dollars to your R&D, that's third-party technical validation that no pitch deck can replicate. Harvard research confirms it: SBIR awardees are significantly more likely to attract venture capital than comparable companies without awards.

This isn't theory. Qualcomm, Moderna, Illumina, and iRobot all used government grants as stepping stones to venture funding. More recently, companies like Electra ($186M raised after SBIR), Ayar Labs ($155M), and AMP Robotics ($91M) have followed the same playbook.

This guide covers the data behind why grants work as investor signals, how to position them in fundraising, and when the signal breaks down.

The data: grants and venture capital outcomes

The certification effect

The foundational research comes from Josh Lerner at Harvard Business School. His study tracked SBIR recipients over a decade and found that awardees grew significantly faster than a matched set of firms and were more likely to attract venture financing. Lerner called this the "certification effect" -- the grant award certifies firm quality in a way that helps investors sort signal from noise.

Important nuance from the same study: the certification effect was strongest for companies in regions with substantial venture capital activity. In other words, the signal works best when investors are around to receive it. An SBIR award in the Bay Area or Boston carries more fundraising weight than the same award in a market with fewer VCs.

Program-level numbers

The aggregate data reinforces Lerner's findings:

That 12% figure deserves context. It might sound low, but it's drawn from all SBIR recipients -- including companies that never intended to raise equity. Among the top 200 NIH Phase II winners (companies with the strongest commercial signals), nearly 1 in 5 also raised venture capital.

Why the signal works

Investors process thousands of pitches. They need fast filters. A government grant provides three things that other signals don't.

1. Independent technical validation

SBIR proposals are reviewed by panels of at least three technical and commercial experts, plus a managing Program Director. This is rigorous, domain-specific peer review. As angel investor John Younger testified before the House Small Business Committee: "A company's receipt of an SBIR award checks an essential box because it means that technical experts have favorably vetted the company's technology, sometimes to an extent that an individual angel may be unable to match."

For deep tech, biotech, and hardware startups -- where investors often lack the domain expertise to evaluate the technology themselves -- this matters enormously. The grant review substitutes for technical due diligence the investor would otherwise need to commission.

2. Non-dilutive runway = negotiating leverage

Cash runway is leverage. It determines how optional your fundraising conversations are, how much pressure you're under to accept unfavorable terms, and how long you can wait for the right partner.

A $305K NSF SBIR Phase I or a $2.1M NIH Phase II extends your runway without setting a valuation or diluting existing shareholders. When you do raise equity, you negotiate from a position of strength -- not desperation. The grant doesn't directly affect your valuation, but it improves every condition under which you negotiate.

3. Mission alignment and market signal

Federal agencies fund technologies that address real problems -- national defense, public health, energy transition, food security. When the NIH funds your diagnostic platform or DARPA funds your AI system, that's not just money. It's a statement that the federal government considers your problem space important enough to fund. For investors evaluating market timing, that signal has weight.

Companies that used grants to raise venture capital

Qualcomm

Received 8 SBIR Phase I awards and 4 Phase II awards totaling $1.5M during its first five years. Co-founder Irwin Jacobs later testified to the U.S. Senate that SBIR was "one of the critical 'stamps of approval' that allowed us to successfully pursue sources of private capital." Today: $135B+ market cap.

Moderna

A different scale, but the same dynamic. Moderna received a $25 million DARPA grant in 2013 to develop mRNA therapeutics -- not SBIR, but a direct federal research award that sent a clear market signal five years before its December 2018 IPO. DARPA described it as "a strong guiding signal that the US government believed that this biotechnology was worthy of investment." The grant wasn't the reason Moderna succeeded, but it was early federal validation that preceded billions in private investment.

Illumina

NCI (National Cancer Institute) SBIR funding helped develop Illumina's core sequencing technology. Founder Dr. Mark Chee said SBIR provided capital for projects that "turned out to be critical to the development of Illumina's core product lines." Annual revenue now exceeds $3.3 billion.

Recent examples

The pattern continues with companies that are fundraising now:

In every case, the SBIR award provided early validation and non-dilutive capital that preceded much larger equity rounds.

How to use grants in your fundraising

In your pitch deck

Include grant funding on your traction or validation slide -- not buried in a financial appendix. Frame it specifically:

Weak: "We received a government grant."

Strong: "Selected by the National Science Foundation from 2,400 applicants for $305K in non-dilutive funding to advance our [specific technical milestone]. Phase I complete. Phase II ($1M) eligible."

Name the agency. Name the competition. Name what the grant validates about your technology. The specificity is what carries credibility.

In investor conversations

Three talking points that land well:

1. The technical validation angle: "A panel of federal experts reviewed our technology and selected us from [X] applicants. That's independent peer review we didn't pay for."

2. The runway angle: "This grant gives us 12 months of funded R&D without dilution. We're raising equity to fund growth, not to keep the lights on."

3. The pipeline angle: "Phase I validates the technology. Phase II is another $1-2M non-dilutive. Phase III is a sole-source follow-on contract. This is a pipeline, not a one-time award."

The timeline pitch

One of the most underused fundraising tools: concrete grant timelines. If you can tell an investor "we submitted to NSF in January, expect feedback by April, and a funding decision by July," you've given them a specific near-term catalyst. Investors love catalysts -- events that change the value of the company on a known timeline.

This came up in a live founder conversation we had at Cada. The founder unprompted told us he mentions his grant strategy to investors: "When I go talk to investors, I'm telling them that I've got a grant strategy too, which they like to hear." The timeline walkthrough gave him concrete talking points for his raise.

When the signal doesn't work

The certification effect is real, but it's not universal. Here are the situations where grants don't help with investors -- or actively complicate the picture.

You're not in a VC-active market

Lerner's research found the signaling effect was concentrated in regions with substantial VC activity. If you're building a company in a market with few investors, the grant is still valuable for its cash and validation -- but the fundraising multiplier effect is weaker because there are fewer investors to receive the signal.

The "SBIR mill" perception

Some investors are wary of companies that win SBIR after SBIR without building a commercial business. Multiple awards with no revenue, no customers, and no equity raised can signal grant-dependency rather than startup ambition. Lerner's data backs this up: multiple awards did not increase performance. One SBIR is a signal. Five SBIRs with nothing else is a red flag.

The fix: use grants to fund R&D while pursuing commercial traction in parallel. Your pitch should show grants as one funding source in a diversified capital strategy, not the entire business model.

Your timeline is too fast

SBIR proposals take 100-300 hours to write, and the cycle from submission to award takes 4-9 months depending on the agency. If you're raising in the next 60 days and need to close fast, a grant application won't help your current round. It might help the next one.

The technology doesn't need federal validation

If you're building a SaaS product with clear product-market fit and growing revenue, investors don't need a government panel to validate your technology. Revenue is a stronger signal than any grant. Grants as investor signals work best for pre-revenue or early-revenue companies with deep tech, where investors struggle to evaluate the technology on their own.

Academic reviewer bias

SBIR proposals are evaluated primarily by university-based scientists, not startup operators or industry experts. As one angel investor noted, reviewers "may overemphasize scientific novelty and underweight important aspects related to product-market fit or strategy." A grant validates your science. It doesn't validate your business. Smart investors know the difference, and you should too.

The strategic play: grants + equity, not grants or equity

The founders who extract the most value from government grants don't choose between grants and venture capital. They use grants strategically within their broader capital stack:

Pre-seed / Seed: Win an SBIR Phase I ($175K-$305K). Use it to fund early R&D and generate data. Raise your seed round with the grant award, technical validation, and preliminary results in hand.

Seed to Series A: Apply for SBIR Phase II ($600K-$2.1M) using Phase I results. The Phase II application is less competitive (~40-60% win rate for Phase I alumni) and the award is substantial. Raise Series A with Phase II funded, R&D de-risked, and a clear Phase III pipeline.

Series A and beyond: Phase III is a sole-source government contract -- meaning the agency can award follow-on work to your company without a new competitive bid. There's no statutory funding ceiling, though actual amounts depend on the agency's budget and your technology's readiness. If your technology has defense, health, or energy applications, this becomes the kind of contracted government revenue pipeline that investors love.

At every stage, the grant does double duty: it funds the work AND signals credibility for the next equity round.

The bottom line

Government grants are not just free money. They're a credibility asset. The peer review process provides technical validation that investors trust, the non-dilutive capital gives you negotiating leverage, and the federal endorsement signals market relevance.

The data is clear: SBIR recipients are more likely to attract venture capital and grow faster than comparable companies without awards. But the signal works best when grants are part of a broader strategy -- funding R&D while building a business, not substituting for one.

If you're raising equity in the next 6-12 months, a grant application submitted now could be one of the strongest cards in your hand by the time you're at the table.

Ready to add government grants to your fundraising strategy?

The companies that do this well don't stumble into grants -- they plan for them. We've written 500+ proposals across 30+ federal agencies and helped companies use SBIR awards to raise stronger equity rounds. Our Strategy Review identifies which grant programs fit your technology and how to time them with your fundraise.